Fulcrum Asset Management’s AbbVie ABBV Stock Holding History

Fulcrum Asset Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Hold	0	–	-$2.58M	–	183
2025 Q1	–	Hold	0	–	–	–	55

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fulcrum Asset Management's ABBV Position: Q2 2026 in Review

Fulcrum Asset Management opened a new position in AbbVie (ABBV) in Q2 2026: 8,198 shares worth $2.08M. The stake represents 0.21% of the portfolio and ranks #124 among its holdings.

4,234 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Fulcrum Asset Management held 8,198 shares of AbbVie worth $2.08M as of Q2 2026.
AbbVie was a new Fulcrum Asset Management position in Q2 2026.
AbbVie made up 0.21% of Fulcrum Asset Management's portfolio in Q2 2026, its #124 holding.
4,234 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Fulcrum Asset Management's 13F filing for Q2 2026, filed 18 Aug 2026.